Controversies in NSAIDs use in XXXX surgery.

@entity1 @entity227 @entity231 @entity7 @entity1103 @entity288
UNASSIGNED: @entity1103 ( @entity1103 ) remains the most common cause of poor visual outcome following @entity231 surgery. Whereas acute @entity1103 may resolve itself spontaneously, some @entity1 will suffer from @entity227 and will be difficult to treat. Although @entity1103 has already been described approximately 50 years ago, its pathophysiology remains uncertain and a multitude of mechanisms have been suggested. As broad as the mechanisms, as many are the treatment options. Topical nonsteroidal anti-inflammatory agents (NSAIDs) and @entity288 either as mono- or combined therapy are a commonly used first line approach. When ineffective, systemic treatment with these agents may be an option. Alternatively, intravitreal application of corticosteroids and anti-vascular endothelial growth factor (anti- @entity7 ) may offer an effective option, if first-line treatment fails. A critical evaluation of the current literature revealed that the optimal treatment of @entity1103 remains unclear and requires further investigation. In addition, prevention should be of foremost importance and remains an open issue. Identification of risk factors, application of NSAIDs and consequent follow-up are potential essential steps in the avoidance of this complication.
